JFJulia A. Ford

Julia A. Ford

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia A. Ford has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Elevated Anti–Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Diagnosis and Risks for Chronic Obstructive Pulmonary Disease or Asthma

    by Alessandra Zaccardelli, Xinyi Liu, Julia A. Ford, Jing Cui, Bing Lu, Su H. Chu, Peter H. Schur, Cameron B. Speyer, Karen H. Costenbader, William H. Robinson, et al.

    Objective: To investigate elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of rheumatoid arthritis (RA) and risks for chronic obstructive pulmonary disease (COPD) or asthma.Methods: We performed a matched cohort study nested within the Nurses’ Health Studies among women who donated blood. Women with incident RA after blood draw (self‐reported, then confirmed by medical records) were each matched to 3 controls by age, cohort, year, and menopausal factors. Pre‐RA ACPA positivity was defined as >99th percentile of control distribution by a research assay or by cyclic citrullinated peptide in a subset. Incident COPD and asthma after index date (date of blood draw) were identified by questionnaires. Cox regression estimated hazard ratios (HRs) for incident COPD or asthma (in separate analyses) associated with pre‐RA, pre‐RA ACPA+, or pre‐RA ACPA– phenotypes each compared to their matched non‐RA controls.Results: We analyzed 283 women who were pre‐RA and 842 controls; blood was donated a mean ± SD of 9.7 ± 5.8 years before RA diagnosis. Fifty‐nine women (20.8%) were pre‐RA ACPA+. There were 107 cases of incident COPD and 105 incident asthma cases during 21,489 person‐years of follow‐up. Pre‐RA ACPA+ was associated with increased COPD risk (HR 3.04 [95% confidence interval (95% CI) 1.33–7.00]) after adjusting for covariates including smoking pack‐years. Pre‐RA ACPA+ had an HR for asthma of 1.74 (multivariable 95% CI 0.72–4.24), similar to the risk of asthma for pre‐RA ACPA– (HR 1.65 [95% CI 1.11–2.46]).Conclusion: Women with elevated ACPA before RA diagnosis had increased risk for developing COPD compared to controls. Women who later developed RA were more likely to develop asthma than controls, regardless of pre‐RA ACPA status.


  • Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study

    by Julia A. Ford, Xinyi Liu, Su H. Chu, Bing Lu, Michael H. Cho, Edwin K. Silverman, Karen H. Costenbader, Carlos A. Camargo, Jeffrey A. Sparks

    Objective: Inflamed airways are hypothesized to contribute to rheumatoid arthritis (RA) pathogenesis due to RA‐related autoantibody production, and smoking is the strongest environmental RA risk factor. However, the role of chronic airway diseases in RA development is unclear. We undertook this study to investigate whether asthma and chronic obstructive pulmonary disease (COPD) were each associated with RA.Methods: We performed a prospective cohort study of 205,153 women in the Nurses’ Health Study (NHS, 1988–2014) and NHSII (1991–2015). Exposures were self‐reported physician‐diagnosed asthma or COPD confirmed by validated supplemental questionnaires. The primary outcome was incident RA confirmed by medical record review by 2 rheumatologists. Covariates (including smoking pack‐years/status) were assessed via biennial questionnaires. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for RA were estimated using Cox regression.Results: We identified 15,148 women with confirmed asthma, 3,573 women with confirmed COPD, and 1,060 incident RA cases during 4,384,471 person‐years (median 24.0 years/participant) of follow‐up in the NHS and NHSII. Asthma was associated with increased RA risk (HR 1.53 [95% CI 1.24–1.88]) compared to no asthma/COPD after adjustment for covariates, including smoking pack‐years/status. Asthma remained associated with increased RA risk when analyzing only never‐smokers (HR 1.53 [95% CI 1.14–2.05]). COPD was also associated with increased RA risk (HR 1.89 [95% CI 1.31–2.75]). The association of COPD with RA was most pronounced in the subgroup of ever‐smokers age >55 years (HR 2.20 [95% CI 1.38–3.51]).Conclusion: Asthma and COPD were each associated with increased risk of incident RA, independent of smoking status/intensity and other potential confounders. These results provide support for the hypothesis that chronic airway inflammation may be crucial in RA pathogenesis.


  • Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody–Positive Patients Without Rheumatoid Arthritis

    by Julia A. Ford, Xinyi Liu, Allison A. Marshall, Alessandra Zaccardelli, Maria G. Prado, Charlene Wiyarand, Bing Lu, Elizabeth W. Karlson, Peter H. Schur, Kevin D. Deane, et al.

    Objective: To investigate the risk of progression to rheumatoid arthritis (RA) in patients who were cyclic citrullinated peptide (CCP) antibody positive without RA at initial presentation.Methods: We performed a retrospective cohort study of CCP+ individuals seen at a US tertiary care system between 2009 and 2018 who were without RA or other systemic rheumatic disease by medical record review at the time of CCP antibody positivity. Progression to classifiable RA was determined through medical record review. We investigated the risk of progression to RA overall and stratified by CCP antibody level (low: >1 to 2× the upper limit of normal [ULN]; medium: >2 to 3× ULN; high: >3× ULN). Multivariable Cox regression estimated the hazard ratio (HR) and 95% confidence interval (95% CI) for RA by CCP antibody level.Results: We identified 340 CCP+ patients who were without RA or other rheumatic disease at baseline. During 1,047 person‐years of follow‐up, 73 patients (21.5%) developed RA. The risk of progression to RA increased with CCP antibody level, with 46.0% (95% CI 34.7–55.3) of patients with high‐level CCP antibodies progressing to RA by 5 years. Compared to low CCP antibody level, medium (HR 3.00 [95% CI 1.32–6.81]) and high (HR 4.83 [95% CI 2.51–9.31]) CCP antibody levels were strongly associated with progression to RA, adjusting for age, sex, body mass index, smoking, family history of RA, and rheumatoid factor level.Conclusion: Among CCP+ patients without RA, the risk for progression to RA increased substantially with increasing CCP antibody level. This study provides further support for close monitoring for development of RA among CCP+ patients and identifying strategies to mitigate this risk.